ScoreWhy is Shenzhen Salubris Pharmaceuticals Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 11.36% and Operating profit at 8.57% over the last 5 years
2
Flat results in Mar 26
- INTEREST(HY) At CNY 11.67 MM has Grown at 39.59%
- DEBT-EQUITY RATIO (HY) Highest at -12.66 %
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.57 times
3
With ROE of 6.99%, it has a expensive valuation with a 3.80 Price to Book Value
- Over the past year, while the stock has generated a return of -15.69%, its profits have risen by 7.4% ; the PEG ratio of the company is 7.3
- At the current price, the company has a high dividend yield of 1.8
4
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 16.83% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -15.69% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shenzhen Salubris Pharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shenzhen Salubris Pharmaceuticals Co., Ltd.
-39.9%
0.89
52.64%
China Shanghai Composite
3.23%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.36%
EBIT Growth (5y)
8.57%
EBIT to Interest (avg)
33.21
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.45
Tax Ratio
1.06%
Dividend Payout Ratio
94.11%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.84%
ROE (avg)
7.07%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
53
Industry P/E
Price to Book Value
3.67
EV to EBIT
64.94
EV to EBITDA
39.19
EV to Capital Employed
4.07
EV to Sales
7.18
PEG Ratio
7.07
Dividend Yield
1.82%
ROCE (Latest)
6.27%
ROE (Latest)
6.99%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 1,214.87 MM
ROCE(HY)
Highest at 7.87%
NET SALES(Q)
Highest at CNY 1,250.7 MM
RAW MATERIAL COST(Y)
Fallen by 1.93% (YoY
-8What is not working for the Company
INTEREST(Q)
At CNY 4.97 MM has Grown at 19.32%
DEBT-EQUITY RATIO
(HY)
Highest at -16.85 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.05 times
Here's what is working for Shenzhen Salubris Pharmaceuticals Co., Ltd.
Operating Cash Flow
Highest at CNY 1,214.87 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
Highest at CNY 1,250.7 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Raw Material Cost
Fallen by 1.93% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shenzhen Salubris Pharmaceuticals Co., Ltd.
Interest
At CNY 4.97 MM has Grown at 19.32%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Debt-Equity Ratio
Highest at -16.85 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 4.05 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Footer loading
